Literature DB >> 23133481

Enterovirus infection in Korean children and anti-enteroviral potential candidate agents.

Kwi Sung Park1, Young Jin Choi, Joon Soo Park.   

Abstract

Although most enterovirus infections are not serious enough to be life threatening, several enteroviruses such as enterovirus 71 are responsible for severe, potentially life-threatening disease. The epidemic patterns of enteroviruses occur regularly during the year, but they may change due to environmental shifts induced by climate change due to global warming. Therefore, enterovirus epidemiological studies should be performed continuously as a basis for anti-viral studies. A great number of synthesized antiviral compounds that work against enteroviruses have been developed but only a few have demonstrated effectiveness in vivo. No proven effective antiviral agents are available for enterovirus disease therapy. The development of a new antiviral drug is a difficult task due to poor selective toxicity and cost. To overcome these limitations, one approach is to accelerate the availability of other existing antiviral drugs approved for antiviral effect against enteroviruses, and the other way is to screen traditional medicinal plants.

Entities:  

Keywords:  Antiviral agents; Enterovirus; Medicinal plants

Year:  2012        PMID: 23133481      PMCID: PMC3488610          DOI: 10.3345/kjp.2012.55.10.359

Source DB:  PubMed          Journal:  Korean J Pediatr        ISSN: 1738-1061


  44 in total

1.  Inhibition of uncoating of poliovirus by arildone, a new antiviral drug.

Authors:  J J McSharry; L A Caliguiri; H J Eggers
Journal:  Virology       Date:  1979-09       Impact factor: 3.616

2.  Synchronous replication of poliovirus RNA: initiation of negative-strand RNA synthesis requires the guanidine-inhibited activity of protein 2C.

Authors:  D J Barton; J B Flanegan
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Virus infection as a function of the host cell life cycle: replication of poliovirus RNA.

Authors:  T Eremenko; A Benedetto; P Volpe
Journal:  J Gen Virol       Date:  1972-07       Impact factor: 3.891

4.  Efficacy of oral WIN 54954 for prophylaxis of experimental rhinovirus infection.

Authors:  R B Turner; F J Dutko; N H Goldstein; G Lockwood; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

5.  Effect of arildone on modifications of poliovirus in vitro.

Authors:  L A Caliguiri; J J McSharry; G W Lawrence
Journal:  Virology       Date:  1980-08       Impact factor: 3.616

6.  Plant antiviral agents; V. 3-Methoxyflavones as potent inhibitors of viral-induced block of cell synthesis.

Authors:  L Van Hoof; D A Vanden Berghe; G M Hatfield; A J Vlietinck
Journal:  Planta Med       Date:  1984-12       Impact factor: 3.352

7.  Genetic and phylogenetic clustering of enteroviruses.

Authors:  T Pöyry; L Kinnunen; T Hyypiä; B Brown; C Horsnell; T Hovi; G Stanway
Journal:  J Gen Virol       Date:  1996-08       Impact factor: 3.891

8.  SCH 38057: a picornavirus capsid-binding molecule with antiviral activity after the initial stage of viral uncoating.

Authors:  E Rozhon; S Cox; P Buontempo; J O'Connell; W Slater; J De Martino; J Schwartz; G Miller; E Arnold; A Zhang
Journal:  Antiviral Res       Date:  1993-05       Impact factor: 5.970

9.  Epidemics of viral meningitis caused by echovirus 6 and 30 in Korea in 2008.

Authors:  Hye-Jin Kim; Byounghak Kang; Seoyeon Hwang; Jiyoung Hong; Kisang Kim; Doo-Sung Cheon
Journal:  Virol J       Date:  2012-02-15       Impact factor: 4.099

Review 10.  Picornavirus inhibitors.

Authors:  L Carrasco
Journal:  Pharmacol Ther       Date:  1994       Impact factor: 12.310

View more
  2 in total

Review 1.  Therapeutic and prevention strategies against human enterovirus 71 infection.

Authors:  Chee Choy Kok
Journal:  World J Virol       Date:  2015-05-12

2.  Antiviral Activity of Hederasaponin B from Hedera helix against Enterovirus 71 Subgenotypes C3 and C4a.

Authors:  Jaehyoung Song; Sang-Gu Yeo; Eun-Hye Hong; Bo-Ra Lee; Jin-Won Kim; Jeonghoon Kim; Hyeongun Jeong; Yongsoo Kwon; Hyunpyo Kim; Sangwon Lee; Jae-Hak Park; Hyun-Jeong Ko
Journal:  Biomol Ther (Seoul)       Date:  2014-01       Impact factor: 4.634

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.